- Research Article
- 10.1016/j.nxmate.2026.101836
Design strategies and emerging trends in BODIPY-, phthalocyanine-, and porphyrin-based photosensitizers for photodynamic anticancer therapy
- Apr 01, 2026
- Next Materials
- Stephanie Nino-Suastegui + 1 more +1
Photodynamic therapy (PDT) is a minimally invasive approach for cancer treatment that relies on light-activated photosensitizers (PSs) to generate reactive oxygen species and induce selective tumor cell death. Despite its clinical potential, the use of conventional PSs is limited by poor aqueous solubility, aggregation, low tumor selectivity, and insufficient singlet oxygen yields. Over the past five years (2021–2025), extensive research has focused on developing next-generation photosensitizers, particularly from three major classes: BODIPYs, phthalocyanines, and porphyrins. Structural modifications, such as donor–acceptor engineering, axial ligand design, metal coordination, and conjugation with biomolecules or chemotherapeutics, have markedly improved their photophysical performance and therapeutic efficacy. Encapsulation into nanocarriers and incorporation of targeting moieties have further enhanced solubility, biocompatibility, and tumor selectivity. Many of these systems demonstrated potent phototoxicity, often at low concentrations, while also offering multifunctional applications including fluorescence imaging, immunogenic cell death induction, and drug or gene delivery. Collectively, these advances highlight how rational design strategies overcome the limitations of earlier generations of photosensitizers and underscore the potential of next-generation systems to advance safer, more effective, and personalized PDT for cancer therapy. This review aims to elucidate how structure-activity relationship (SAR) insights have been leveraged to rationally design photosensitizers with enhanced cytotoxicity and tumor selectivity by comparing dominant photosensitizer scaffold.
Read more